So You Think Inhaled Insulin Can't Make It. Wanna Bet?

Alfred Mann does, and he's betting nearly $1 billion that his inhaled insulin--Technosphere--will be cleared for sale in the United States. Embarking on an area of the market that proved unsuccessful for Eli Lilly, Pfizer, and Novo Nordisk, Mann's company, MannKind Corp., will be releasing data from clinical trials involving Technosphere tomorrow, reports.

September 16, 2008

1 Min Read
So You Think Inhaled Insulin Can't Make It. Wanna Bet?

Despite a lack of confidence from investors, Mann believes his product will succeed and that the product could bring in more than $1 billion annually. One of the advantages of Technosphere is its fast absorption rate. Upon inhalation, the insulin reaches a peak bloodstream level in less than 15 minutes versus injectable products that can take up to 90 minutes.The safety issue will be critical to product approval. According to Mann, Technosphere is different than Pfizer's Exubera inhaled insulin (Six patients involved in the Exubera clinical trial developed lung cancer). He said that following the Pfizer report, an independent safety board found no signs of emerging lung cancer in MannKind's trials.And even if Technosphere is approved by FDA, market acceptance won't be quick or easy. Given past failures with inhaled insulin, investors won't have confidence in the product, and doctors will be faced with explaining a completely new way of taking insulin to patients.UPDATE: Pfizer and Mann collaborate.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like